Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Turning Point Therapeutics Inc. (TPTX) Tops Q2 EPS by 7c
August 9, 2021 4:43 PM EDTTurning Point Therapeutics Inc. (NASDAQ: TPTX) reported Q2 EPS of ($1.14), $0.07 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $5.2 thousand, versus $0 reported last year.
Cash, cash equivalents and marketable securities at June 30, 2021 totaled approximately $1.1 billion. Net cash used during... More
